SCHEMBL5083242

SCHEMBL5083242

O=C(O)c1cn(C23CC(C2)C3)c2nc(N3CC4CCC(C3)N4)c(F)cc2c1=O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHA2 P29317 1/20 0.49
FLT4 P35916 1/20 0.49
GSK3B P49841 1/20 0.49
RARB P10826 1/20 0.49
TBXAS1 P24557 1/20 0.49
SLC6A3 Q01959 1/20 0.49
LMNA P02545 4/20 0.48
CYP2C9 P11712 3/20 0.48
ATP6V1B2 P21281 1/20 0.48
TBXA2R P21731 1/20 0.48
EDNRA P25101 1/20 0.48
TARBP2 Q15633 1/20 0.48
DPP4 P27487 6/20 0.47
KMT2A Q03164 1/20 0.46
KDM4E B2RXH2 4/20 0.46
HSD17B10 Q99714 4/20 0.46
ALDH1A1 P00352 3/20 0.46
HPGD P15428 3/20 0.46
POLB P06746 1/20 0.46
XBP1 P17861 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5080289 0.89 EPHA2 (0.49) EPHA2FLT4GSK3BRARBTBXAS1
SCHEMBL5082857 0.86 DPP4 (0.51) EPHA2FLT4GSK3BRARBTBXAS1
SCHEMBL5080649 0.85 KMT2A (0.52) EPHA2FLT4GSK3BRARBTBXAS1
SCHEMBL5083883 0.85 LMNA (0.65) EPHA2FLT4GSK3BRARBTBXAS1
SCHEMBL5086571 0.84 KMT2A (0.65) EPHA2FLT4GSK3BRARBTBXAS1
SCHEMBL5086558 0.84 KMT2A (0.65) EPHA2FLT4GSK3BRARBTBXAS1
SCHEMBL5141828 0.84 DPP4 (0.45) EPHA2FLT4GSK3BRARBTBXAS1
SCHEMBL5080362 0.83 DPP4 (0.52) EPHA2FLT4GSK3BRARBTBXAS1
SCHEMBL5083140 0.83 DPP4 (0.52) EPHA2FLT4GSK3BRARBTBXAS1
SCHEMBL5083223 0.83 DPP4 (0.52) EPHA2FLT4GSK3BRARBTBXAS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-1990006307-A2 ANTIBACTERIAL QUINOLONE COMPOUNDS THE UPJOHN COMPANY (US) 1990-06-14 WO claimed
US-20080044390-A1 Methods and compositions for the treatment of neurodegenerative disorders CHDI, INCORPORATED 2008-02-21 US disclosed
US-5385906-A Treating gramnegative and grampositive bacterial infections THE UPJOHN COMPANY (US) 1995-01-31 US disclosed
US-5262417-A Antibacterial quinolone compounds THE UPJOHN COMPANY (US) 1993-11-16 US disclosed
WO-1990006307-A2 ANTIBACTERIAL QUINOLONE COMPOUNDS THE UPJOHN COMPANY (US) 1990-06-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080044390-A1 Methods and compositions for the treatment of neurodegenerative disorders HTT, SNCA, NLN EPHA2 2318/4885FLT4 4759/4885GSK3B 463/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.